Ralph D'Agostino to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Ralph D'Agostino has written about Xenograft Model Antitumor Assays.
Connection Strength
0.113
-
Renfrow JJ, Soike MH, West JL, Ramkissoon SH, Metheny-Barlow L, Mott RT, Kittel CA, D'Agostino RB, Tatter SB, Laxton AW, Frenkel MB, Hawkins GA, Herpai D, Sanders S, Sarkaria JN, Lesser GJ, Debinski W, Strowd RE. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Sci Rep. 2020 09 16; 10(1):15195.
Score: 0.046
-
Jimenez H, Wang M, Zimmerman JW, Pennison MJ, Sharma S, Surratt T, Xu ZX, Brezovich I, Absher D, Myers RM, DeYoung B, Caudell DL, Chen D, Lo HW, Lin HK, Godwin DW, Olivier M, Ghanekar A, Chen K, Miller LD, Gong Y, Capstick M, D'Agostino RB, Munden R, Merle P, Barbault A, Blackstock AW, Bonkovsky HL, Yang GY, Jin G, Liu L, Zhang W, Watabe K, Blackman CF, Pasche BC. Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2?T-type voltage-gated calcium channels and Ca2+ influx. EBioMedicine. 2019 Jun; 44:209-224.
Score: 0.042
-
Blackham AU, Northrup SA, Willingham M, D'Agostino RB, Lyles DS, Stewart JH. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. Surgery. 2013 Mar; 153(3):333-43.
Score: 0.026